Multiple Myeloma Hub

During the European School of Haematology (ESH) 5th Translational Research E-Conference on Multiple Myeloma, the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, University of Würzburg, Würzburg, DE, about novel immunotherapies. Bispecific antibodies and chimeric antigen receptor (CAR) T cells represent a novel interesting therapeutic option for patients with multiple myeloma. In this...

During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the MM Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft- versus -h...

During COMy 2020, Multiple Myeloma Hub Steering Committee Member Paul Richardson, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about advances in the novel, peptide-conjugated alkylator, melphalan flufenamide (melflufen). Melflufen has been successful in overcoming resistance to standard chemotherapeutics as well as novel agents, such as proteasome inhibitors and immu...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Katja Weisel, University Cancer Center Hamburg, Hamburg, DE. In this podcast she discusses the quadruplet combination of isatuximab with carfilzomib, lenalidomide and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. In this podcast, Katja Weisel des...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Paul Richardson, Dana-Farber Cancer Institute, Boston, US. In this podcast he discusses cereblon E3 ligase modulators (CELMoDs) as a novel approach in the treatment of relapsed/refractory multiple myeloma. Paul Richardson describes how preclinical data have shown CC-92480 to h...

During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub was pleased to speak to Saad Usmani, Levine Cancer Institute, Atrium Health, Charlotte, US. In this podcast he discusses data from three clinical trials, which address the use of quadruplet treatments and anti-BCMA therapy for multiple myeloma. He describes the progression free survival, overall surviva...

During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM. Here, Nikhil Munshi highlights the positive shift in survival outcomes of patients with high-risk MM in recent years, owing to emerging treatments and diagnostic techniques. Three major points are discussed: 1. Who is high risk? 2. What are the characteristic...

During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Steering Committee Member Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, AT. This podcast outlines a study that aimed to determine the impact of the oral microbiome in patients uniformly treated with ixazomib + thalidomide + dexamethasone combination therapy for the treatment of r...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myleoma Hub was pleased to speak to Adam Cohen, University of Pennsylvania, Philadelphia, US. In this podcast, he discussed the use of BFCR4350A, a novel bispecific FcRH5:CD3 T-cell engaging antibody, in patients with relapsed/refractory multiple myeloma. Adam Cohen provides us with insights from pre-clinical data...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US. In this podcast, he discusses the recent updates from the KarMMa phase II trial (NCT03361748). in patients with relapsed/refractory multiple myeloma. Nikhil Munshi describes the mechanism of action of the idecabtagene vicl...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Jesus Berdeja, Sarah Cannon Research Institute, Nashville, US. In this podcast, he discusses the latest updates from the CARTITUDE-1. This was a phase I/IIb study of JNJ-4528, a B cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR T)-cell therapy in patient...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Amrita Krishnan, City of Hope, Duarte, US. In this podcast, she discussed the phase I data of TAK-079, a novel anti-CD38 monoclonal antibody, in a heavily pre-treated population of patients with multiple myeloma. She begins be describing the uniqueness of TAK-079 over other appr...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked: Should we use carfilzomib, lenalidomide, and dexamethasone (KRd) or bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma (NDMM)? In this podcast he describes the results of the E...

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Elizabeth O'Donnell, Massachusetts General Hospital, Boston, US. We asked: what is the optimal treatment for bone lesions, including patients with renal insufficiency? In this podcast, Elizabeth O'Donnell discusses how bone-directed therapy is an important component of multipl...

During COMy 2020, Multiple Myeloma (MM) Hub steering committee member, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, spoke to the MM Hub about the recent advances in our understanding of myeloma progression. The question remains for patients with smoldering MM: when should therapeutic intervention begin? Here, Irene Ghobrial discusses the need for more robust disease-characterizing and...

During the American Society of Clinical Oncology (ASCO) 2020 Meeting, the Multiple Myeloma Hub was pleased to speak to Enrique M. Ocio, Marqués de Valdecilla University Hospital, Santander, ES. In this podcast, Enrique M. Ocio discusses the results of the phase I/II trial that evaluated quadruplet combinations in patients with transplant-ineligible multiple myeloma. Enrique M. Ocio begins by descr...

During COMy 2020, Paula Rodriguez Otero, Clínica Universidad de Navarra, Pamplona, ES, spoke to the Multiple Myeloma (MM) Hub. We asked: How should we treat elderly patients with newly diagnosed MM?  A number of factors may influence a patient's eligibility for, and outcome to, different treatments in the MM setting. Here, Paula Rodriguez Otero discusses these factors and outlines the availab...

During COMy 2020, Enrique Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the Multiple Myeloma (MM) Hub about resistance mechanisms to current standard of care and how to overcome them. Although advances in treatment options for MM have improved the outcome of patients in recent years, resistance remains a problem and MM is still considered an incurable disease. Here, Enri...

During COMy 2020, Artur Jurczyszyn, Jagiellonian University Medical College, Krakow, PL, spoke to the Multiple Myeloma Hub. We asked: What is plasma cell leukemia and what are the latest advances in treatment? In this podcast, Artur Jurczyszyn talks about the classifications of plasma cell leukemia and the importance of outlining a plasma cell prognostic index for use in clinical practice. The dat...